Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by PoorOpinionon Mar 16, 2018 5:04pm

154 Views

Post# 27731081

RE:RE:RE:RE:RE:I am baffled

kingdaddymack wrote: For longs here historically has ate delivered results on time? Week on march 19th, thats 5 trading days, ofcouse earlier in the week much better.

Generally yes, but they've never quite promised data in such a specific way before. Generally they go about stuff in a fairly straightforward way. Delays are a low concern for me, they've re-iterated next week as the release date, no reason to assume outherwise.

Bullboard Posts

Pro Women’s Hockey League comes to NHL 25 in December